Compare Garmin Ltd. (GRMN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Sanofi SA — how do they compare? Garmin Ltd. trades at $271.28 (market cap $51.77B), while Sanofi SA trades at $40.1 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Sanofi SA for 94 Days on average.
| GRMN | SNY | |
|---|---|---|
Market Cap | $51.77B | $95.18B |
Volume | 961,398 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $313.16 | $52.34 |
52-Week Low | $187.10 | $39.51 |
Typical Hold Time | 83 Days | 94 Days |
Enterprise Value | $49.28B | $114.48B |
Dividend Yield | 1.56% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% today, showing strong fundamentals with consistent earnings beats and robust profitability. The company maintains impressive gross margins of 60.08% and net income margins of 24.47%, supported by steady revenue growth from $4.9B in 2022 to $7.25B in 2025. Recent positive developments include multiple product awards and new feature rollouts across marine, fitness, and automotive segments, though technical indicators suggest near-term bearish pressure.
Garmin presents a compelling investment case with strong financial performance and analyst consensus target of $320.25 (16% upside). However, elevated valuation ratios (P/E 28.5, P/S 6.97) and technical bearish signals warrant caution. Key risks include competitive pressures in wearable technology and potential economic sensitivity in consumer discretionary spending.
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
